Patrick Biggar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Patrick Biggar has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Markus Ketteler
Nephrology, Coburg Clinic and KfH-Dialysis Center, Coburg, Germany
4 shared publications Andreas Walper
1 shared publicationArndt Petermann
1 shared publicationFrank Leistikow
1 shared publicationGheun-Ho Kim
Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
1 shared publicationHansjorg Rothe
1 shared publication
Latest Publications
- Open Access
- 30 September 2017
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 36 (3) , 209-223
Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
Patrick Biggar, Gheun-Ho Kim. Kidney Res Clin Pract 2017;36:209-23. https://doi.org/10.23876/j.krcp.2017.36.3.209
- 30 September 2017
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 36 (3) , 209-223
Open AccessTreatment of renal anemia: Erythropoiesis stimulating agents and beyond
Patrick Biggar, Gheun-Ho Kim. Kidney Res Clin Pract 2017;36:209-23. https://doi.org/10.23876/j.krcp.2017.36.3.209
- 1 December 2016
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 86 (12) , 310-318
A prospective observational study of effectiveness and safety of iron isomaltoside in patients with chronic renal failure and iron deficiency anemia
The aim of this study was to investigate the effectiveness, safety, and tolerability of iron isomaltoside in routine practical care of iron deficiency anemia (IDA) in patients with chronic renal failure. The study included 698 patients with IDA on dialysis or with nondialysis chronic kidney disease (CKD) stages 3 - 5 designated by their physicians for treatment with iron isomaltoside. Data were recorded at baseline and after 3 and 9 months. Effectiveness data included measurement of hemoglobin (Hb), hematocrit, i-iron, transferrin saturation (TSAT), and i-ferritin. Safety data included adverse events and safety laboratory variables. Following administration of a mean cumulative dose of 2,574 mg isomaltoside over 9 months, initial average Hb increased from 11.0 g/dL to 11.6 g/dL, TSAT from 19.4% to 28.3%, and i-ferritin from 320 µg/L to 642 µg/L, demonstrating a positive effect of iron isomaltoside on iron deficiency. In addition, there was a significant reduction in the use of erythropoiesis-stimulating agents (ESAs) (regarding epoetin α, initial mean dose 40,688 IU/month, final dose 35,665 IU/month, -13.7%, p < 0.001). No drug-related adverse events were reported. Furthermore, safety parameters including i-phosphate indicated no abnormal changes. Iron isomaltoside demonstrated very good effectiveness and tolerability in patients with stage 3 - 5 CKD, including an ESA saving effect. .
- 1 December 2016
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 86 (12) , 310-318
A prospective observational study of effectiveness and safety of iron isomaltoside in patients with chronic renal failure and iron deficiency anemia
The aim of this study was to investigate the effectiveness, safety, and tolerability of iron isomaltoside in routine practical care of iron deficiency anemia (IDA) in patients with chronic renal failure. The study included 698 patients with IDA on dialysis or with nondialysis chronic kidney disease (CKD) stages 3 - 5 designated by their physicians for treatment with iron isomaltoside. Data were recorded at baseline and after 3 and 9 months. Effectiveness data included measurement of hemoglobin (Hb), hematocrit, i-iron, transferrin saturation (TSAT), and i-ferritin. Safety data included adverse events and safety laboratory variables. Following administration of a mean cumulative dose of 2,574 mg isomaltoside over 9 months, initial average Hb increased from 11.0 g/dL to 11.6 g/dL, TSAT from 19.4% to 28.3%, and i-ferritin from 320 µg/L to 642 µg/L, demonstrating a positive effect of iron isomaltoside on iron deficiency. In addition, there was a significant reduction in the use of erythropoiesis-stimulating agents (ESAs) (regarding epoetin α, initial mean dose 40,688 IU/month, final dose 35,665 IU/month, -13.7%, p < 0.001). No drug-related adverse events were reported. Furthermore, safety parameters including i-phosphate indicated no abnormal changes. Iron isomaltoside demonstrated very good effectiveness and tolerability in patients with stage 3 - 5 CKD, including an ESA saving effect. .
- 1 October 2015
- Published by Oxford University Press (OUP)
- p. 869-876
Epidemiology of calcium, phosphate, and parathyroid hormone disturbances in chronic kidney disease
- 1 October 2015
- Published by Oxford University Press (OUP)
- p. 869-876
Epidemiology of calcium, phosphate, and parathyroid hormone disturbances in chronic kidney disease
- 21 April 2014
- Published by Bentham Science Publishers Ltd. in Recent Patents on Biomarkers
- Vol. 4 (1) , 53-59
Calcimimetic Drugs and Biomarkers
The calcium-sensing receptor is expressed almost ubiquitously throughout the human body, and is essential for calcium homeostasis and is involved in several disease pathomechanisms. Mainly in nephrology, therapeutic compounds acting on the receptor are already in use in clinical routine practice. The era of calcimimetic therapy, which commenced 10 years ago with the approval of the first-in-class compound cinacalcet HCl, has recently entered into a new phase with the arrival of velcalcetide (AMG416). Since both compounds bind to different sites at the receptor molecule, genetic polymorphism panels could conceivably play a role in future for the prediction of the best choice for any given patient. If velcalcetide, which has currently just passed phase-III-trials, is also approved for therapeutic use, this will increase the spectrum of choices and the clinician will have to make decisions about which calcimimetic drug to give to which patient. This decision would probably have to be based on various considerations including biomarkers. This article summarizes the present situation regarding patents on biomarkers dealing with the calcium-sensing receptor and genetic polymorphisms.
- 21 April 2014
- Published by Bentham Science Publishers Ltd. in Recent Patents on Biomarkers
- Vol. 4 (1) , 53-59
Calcimimetic Drugs and Biomarkers
The calcium-sensing receptor is expressed almost ubiquitously throughout the human body, and is essential for calcium homeostasis and is involved in several disease pathomechanisms. Mainly in nephrology, therapeutic compounds acting on the receptor are already in use in clinical routine practice. The era of calcimimetic therapy, which commenced 10 years ago with the approval of the first-in-class compound cinacalcet HCl, has recently entered into a new phase with the arrival of velcalcetide (AMG416). Since both compounds bind to different sites at the receptor molecule, genetic polymorphism panels could conceivably play a role in future for the prediction of the best choice for any given patient. If velcalcetide, which has currently just passed phase-III-trials, is also approved for therapeutic use, this will increase the spectrum of choices and the clinician will have to make decisions about which calcimimetic drug to give to which patient. This decision would probably have to be based on various considerations including biomarkers. This article summarizes the present situation regarding patents on biomarkers dealing with the calcium-sensing receptor and genetic polymorphisms.
- 23 January 2014
- Published by Springer Nature in Der Nephrologe
- Vol. 9 (2) , 149-150
Differenzierte kardiovaskuläre Aspekte der aktivierten Vitamin-D-Analoga
- 23 January 2014
- Published by Springer Nature in Der Nephrologe
- Vol. 9 (2) , 149-150
Differenzierte kardiovaskuläre Aspekte der aktivierten Vitamin-D-Analoga
- 15 October 2013
- Published by Georg Thieme Verlag KG in Dialyse aktuell
- Vol. 17 (08) , 426-436
Kalzium- und Phosphatbilanz bei Niereninsuffizienz - Wann und wie soll therapiert werden?
In den letzten 2 Jahrzehnten hat sich unser Verständnis für den menschlichen Kalzium- und Phosphathaushalt wesentlich geändert. Noch vor nicht allzu langer Zeit ging man davon aus, dass eine erhöhte Kalziumzufuhr günstig sei, um einen gesunden Knochenaufbau zu ermöglichen, und dass zumindest leicht erhöhte Serum-Phosphat-Werte keine nachteiligen Wirkungen bei Patienten mit chronischer Niereninsuffizienz hätten. Heute weiß man aus zahlreichen Beobachtungs- sowie In-vitro-Studien, dass sowohl Kalzium als auch Phosphat eine zentrale Triggerfunktion für den Prozess der Weichteil- bzw. der Gefäßverkalkung und somit für die Prognose haben. Dementsprechend werden neben anderen therapeutischen Optionen auch kalziumfreie Phosphatbinder eingesetzt, um die Kalziumbeladung und die Phosphataufnahme zu reduzieren. Angesichts der derzeit widersprüchlichen Datenlage bezüglich der Applikation von Phosphatsenkern bei präterminaler Niereninsuffizienz und nur tendenziell erhöhtem Serumphosphat sollten Phosphatbinder momentan nur bei sichtbarer Hyperphosphatämie verabreicht werden. Darüber hinaus bleibt jedoch eine Reduktion des Phosphatgehalts in der täglichen Nahrung eine Herausforderung, solange keine adäquate Kennzeichnung der Lebensmittel erfolgt. In the last 2 decades, our understanding of the human calcium and phosphate homeostasis has changed dramatically. Following initial perceptions that calcium supplementation was advantageous for normal bone development and that moderately elevated phosphate levels were not detrimental to patients with chronic kidney disease, numerous observational and in vitro studies have shown that calcium and phosphate possess a central trigger function regarding initiation of soft tissue calcification, i. e. in the vessels, and thus are both determinants of prognosis. In this context, calcium-free phosphate binders are employed among other interventions to reduce corporeal calcium and phosphate loading. In view of present contradictory data regarding phosphate binder therapy in patients with preterminal chronic kidney disease but only marginally elevated serum phosphate levels, phosphate binders should presently only be administered when hyperphosphatemia is visible. Furthermore, however, a reduction in the daily nutrition remains enigmatic as long as adequate food supplement declaration is not enforced.
- 15 October 2013
- Published by Georg Thieme Verlag KG in Dialyse aktuell
- Vol. 17 (08) , 426-436
Kalzium- und Phosphatbilanz bei Niereninsuffizienz - Wann und wie soll therapiert werden?
In den letzten 2 Jahrzehnten hat sich unser Verständnis für den menschlichen Kalzium- und Phosphathaushalt wesentlich geändert. Noch vor nicht allzu langer Zeit ging man davon aus, dass eine erhöhte Kalziumzufuhr günstig sei, um einen gesunden Knochenaufbau zu ermöglichen, und dass zumindest leicht erhöhte Serum-Phosphat-Werte keine nachteiligen Wirkungen bei Patienten mit chronischer Niereninsuffizienz hätten. Heute weiß man aus zahlreichen Beobachtungs- sowie In-vitro-Studien, dass sowohl Kalzium als auch Phosphat eine zentrale Triggerfunktion für den Prozess der Weichteil- bzw. der Gefäßverkalkung und somit für die Prognose haben. Dementsprechend werden neben anderen therapeutischen Optionen auch kalziumfreie Phosphatbinder eingesetzt, um die Kalziumbeladung und die Phosphataufnahme zu reduzieren. Angesichts der derzeit widersprüchlichen Datenlage bezüglich der Applikation von Phosphatsenkern bei präterminaler Niereninsuffizienz und nur tendenziell erhöhtem Serumphosphat sollten Phosphatbinder momentan nur bei sichtbarer Hyperphosphatämie verabreicht werden. Darüber hinaus bleibt jedoch eine Reduktion des Phosphatgehalts in der täglichen Nahrung eine Herausforderung, solange keine adäquate Kennzeichnung der Lebensmittel erfolgt. In the last 2 decades, our understanding of the human calcium and phosphate homeostasis has changed dramatically. Following initial perceptions that calcium supplementation was advantageous for normal bone development and that moderately elevated phosphate levels were not detrimental to patients with chronic kidney disease, numerous observational and in vitro studies have shown that calcium and phosphate possess a central trigger function regarding initiation of soft tissue calcification, i. e. in the vessels, and thus are both determinants of prognosis. In this context, calcium-free phosphate binders are employed among other interventions to reduce corporeal calcium and phosphate loading. In view of present contradictory data regarding phosphate binder therapy in patients with preterminal chronic kidney disease but only marginally elevated serum phosphate levels, phosphate binders should presently only be administered when hyperphosphatemia is visible. Furthermore, however, a reduction in the daily nutrition remains enigmatic as long as adequate food supplement declaration is not enforced.
- 1 May 2013
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 79 (5) , 335-350
ESA therapy – the quest continues: anemia treatment following recent national and international recommendations 2011 and 2012
The development of ESA (Erythropoiesis Stimulating Agents) revolutionized the treatment of renal anemia. However, the initial euphoria has abated and, in the last few years, studies have shown that ESAs should not be administered without caution as the rate of cardiovascular events and possibly tumor related deaths may increase with over-augmented hemoglobin levels. Renal anemia therapy is discussed against the background of recent decisions to lower the recommended hemoglobin target ranges in chronic kidney disease (CKD) patients on ESAs, thus, necessitating a redefinition of treatment quality criteria and exposing areas requiring further research.
- 1 May 2013
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 79 (5) , 335-350
ESA therapy – the quest continues: anemia treatment following recent national and international recommendations 2011 and 2012
The development of ESA (Erythropoiesis Stimulating Agents) revolutionized the treatment of renal anemia. However, the initial euphoria has abated and, in the last few years, studies have shown that ESAs should not be administered without caution as the rate of cardiovascular events and possibly tumor related deaths may increase with over-augmented hemoglobin levels. Renal anemia therapy is discussed against the background of recent decisions to lower the recommended hemoglobin target ranges in chronic kidney disease (CKD) patients on ESAs, thus, necessitating a redefinition of treatment quality criteria and exposing areas requiring further research.
- 21 March 2013
- p. 18-24
[Importance of the different i.v. iron generations for everyday medical practice].
Iron deficiency and anaemia occur in particular in women or as comorbid conditions to a varietyof chronic diseases. Besides oral preparations, parenteral iron therapies are also available for the treatment of iron deficiency or anaemia. In the light of the growing importance and increasing number of parenteral iron preparations, theirpharmacology and application as well as the chronology of their approvals and thecharacteristicsof the various preparations are presented herefor comparison. Review. To date, there are three different generations of parenteral iron preparations, which differ in terms of stability, safety and dosage. In particular, the active substances of the third generation, ferric carboxymaltose, iron isomaltoside and ferumoxytol are characterised by high complex stability and comparable safety, also allowing rapid application of high doses of iron. High molecular weight iron dextran, as a representative of 1st generation iron preparations, should no longer be used if possible, as more recent i.v. iron preparations are available with considerably lower risk of serious anaphylactic reactions. Ferrous gluconate and iron sucrose, as representatives of the 2nd generation, are very efficient preparations, but they require frequent visits to the clinic or the doctor, as they may only be administered in low doses because of labile iron complexes. The three 3rd generation parenteral iron formulations have advantages in handling in everyday practice, since they offer comparably good safety profiles, high complex stability and thus the possibility of rapid application of high doses of iron up to the total cumulative dose. Furthermore, test doses are not required with these preparations, which also simplifies their use.
- 21 March 2013
- p. 18-24
[Importance of the different i.v. iron generations for everyday medical practice].
Iron deficiency and anaemia occur in particular in women or as comorbid conditions to a varietyof chronic diseases. Besides oral preparations, parenteral iron therapies are also available for the treatment of iron deficiency or anaemia. In the light of the growing importance and increasing number of parenteral iron preparations, theirpharmacology and application as well as the chronology of their approvals and thecharacteristicsof the various preparations are presented herefor comparison. Review. To date, there are three different generations of parenteral iron preparations, which differ in terms of stability, safety and dosage. In particular, the active substances of the third generation, ferric carboxymaltose, iron isomaltoside and ferumoxytol are characterised by high complex stability and comparable safety, also allowing rapid application of high doses of iron. High molecular weight iron dextran, as a representative of 1st generation iron preparations, should no longer be used if possible, as more recent i.v. iron preparations are available with considerably lower risk of serious anaphylactic reactions. Ferrous gluconate and iron sucrose, as representatives of the 2nd generation, are very efficient preparations, but they require frequent visits to the clinic or the doctor, as they may only be administered in low doses because of labile iron complexes. The three 3rd generation parenteral iron formulations have advantages in handling in everyday practice, since they offer comparably good safety profiles, high complex stability and thus the possibility of rapid application of high doses of iron up to the total cumulative dose. Furthermore, test doses are not required with these preparations, which also simplifies their use.
- 1 March 2013
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 155 (S2) , 18-24
Bedeutung der verschiedenen i.v.-Eisengenerationen für den medizinischen Alltag
- 1 March 2013
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 155 (S2) , 18-24
Bedeutung der verschiedenen i.v.-Eisengenerationen für den medizinischen Alltag
- 27 October 2010
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 11 (16) , 2739-2750
Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III – V)
Importance of the field: Altered mineral metabolism in chronic kidney disease (CKD) is associated with increased morbidity, mortality, hospitalization, cost of care and reduced quality of life. Phosphorus control, one component of CKD metabolic derangements, is potentially related to impaired outcomes and has significant room for improvement. Areas covered in this review: Historical, present and future aspects of treatment of hyperphosphatemia focusing on sevelamer hydrochloride and sevelamer carbonate. What the reader will gain: Comprehensive insight into the background and controversies regarding phosphate binders. Take home message: While calcium-free phosphate binders with a sevelamer backbone may offer therapeutic advantages for CKD patients at risk, more studies comprising significant patient numbers are warranted to answer compelling clinical questions.
- 27 October 2010
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 11 (16) , 2739-2750
Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III – V)
Importance of the field: Altered mineral metabolism in chronic kidney disease (CKD) is associated with increased morbidity, mortality, hospitalization, cost of care and reduced quality of life. Phosphorus control, one component of CKD metabolic derangements, is potentially related to impaired outcomes and has significant room for improvement. Areas covered in this review: Historical, present and future aspects of treatment of hyperphosphatemia focusing on sevelamer hydrochloride and sevelamer carbonate. What the reader will gain: Comprehensive insight into the background and controversies regarding phosphate binders. Take home message: While calcium-free phosphate binders with a sevelamer backbone may offer therapeutic advantages for CKD patients at risk, more studies comprising significant patient numbers are warranted to answer compelling clinical questions.